Survival After Surgical Resection of Stage IV Esophageal Cancer

Sahar A. Saddoughi, J. Matthew Reinersman, Yuriy O. Zhukov, James Taswell, Kristin Mara, S. William Harmsen, Shanda H. Blackmon, Stephen D. Cassivi, Francis Nichols, K. Robert Shen, Dennis A Wigle, Mark S. Allen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Five-year survival of stage IV esophageal cancer is rare. The treatment of advanced esophageal cancer is typically palliative and the role of surgery remains controversial. We sought to understand the impact of curative surgery on survival and identify any favorable tumor or patient characteristics that might make surgical resection appropriate when treating stage IV esophageal cancer. Methods A retrospective review of 3,500 esophagectomies performed at our institution from 1985 to 2013 identified 52 (1.5%) patients with stage IV esophageal cancer who underwent surgical resection with intent for cure. In 46 (88.5%) patients, M1 disease was discovered at the time of surgery and 6 (11.5%) patients had known M1 disease prior to surgery. Results Median age at the time of surgery was 60 years (range, 31 to 81 years). The majority of patients were men (82.7%) with adenocarcinoma (88.5%). Neoadjuvant therapy was used in 18 (34.6%) patients; all patients operated on after 1999 received neoadjuvant therapy. An Ivor Lewis esophagectomy was performed in 39 (75%) patients. Follow-up was complete in all patients for a median of 324 days (range, 4 days to 8.5 years). Overall, 1-year survival was 29% and 5-year survival was 6%. There was no significant difference in survival between patients with known preoperative versus intraoperative discovery of M1 disease. Factors associated with improved survival included neoadjuvant treatment, low T stage, and lack of alcohol use. Conclusions Few patients with stage IV esophageal cancer survive long term after surgical resection, though 5-year survival can occur. Our current recommendation is that esophagectomy should not be performed for stage IV disease.

Original languageEnglish (US)
Pages (from-to)261-266
Number of pages6
JournalAnnals of Thoracic Surgery
Volume103
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Esophageal Neoplasms
Survival
Neoadjuvant Therapy
Esophagectomy
Palliative Care
Adenocarcinoma
Alcohols

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Saddoughi, S. A., Reinersman, J. M., Zhukov, Y. O., Taswell, J., Mara, K., Harmsen, S. W., ... Allen, M. S. (2017). Survival After Surgical Resection of Stage IV Esophageal Cancer. Annals of Thoracic Surgery, 103(1), 261-266. https://doi.org/10.1016/j.athoracsur.2016.06.070

Survival After Surgical Resection of Stage IV Esophageal Cancer. / Saddoughi, Sahar A.; Reinersman, J. Matthew; Zhukov, Yuriy O.; Taswell, James; Mara, Kristin; Harmsen, S. William; Blackmon, Shanda H.; Cassivi, Stephen D.; Nichols, Francis; Shen, K. Robert; Wigle, Dennis A; Allen, Mark S.

In: Annals of Thoracic Surgery, Vol. 103, No. 1, 01.01.2017, p. 261-266.

Research output: Contribution to journalArticle

Saddoughi, SA, Reinersman, JM, Zhukov, YO, Taswell, J, Mara, K, Harmsen, SW, Blackmon, SH, Cassivi, SD, Nichols, F, Shen, KR, Wigle, DA & Allen, MS 2017, 'Survival After Surgical Resection of Stage IV Esophageal Cancer', Annals of Thoracic Surgery, vol. 103, no. 1, pp. 261-266. https://doi.org/10.1016/j.athoracsur.2016.06.070
Saddoughi SA, Reinersman JM, Zhukov YO, Taswell J, Mara K, Harmsen SW et al. Survival After Surgical Resection of Stage IV Esophageal Cancer. Annals of Thoracic Surgery. 2017 Jan 1;103(1):261-266. https://doi.org/10.1016/j.athoracsur.2016.06.070
Saddoughi, Sahar A. ; Reinersman, J. Matthew ; Zhukov, Yuriy O. ; Taswell, James ; Mara, Kristin ; Harmsen, S. William ; Blackmon, Shanda H. ; Cassivi, Stephen D. ; Nichols, Francis ; Shen, K. Robert ; Wigle, Dennis A ; Allen, Mark S. / Survival After Surgical Resection of Stage IV Esophageal Cancer. In: Annals of Thoracic Surgery. 2017 ; Vol. 103, No. 1. pp. 261-266.
@article{4f2308b1c1164c599c2b263fec37dbc7,
title = "Survival After Surgical Resection of Stage IV Esophageal Cancer",
abstract = "Background Five-year survival of stage IV esophageal cancer is rare. The treatment of advanced esophageal cancer is typically palliative and the role of surgery remains controversial. We sought to understand the impact of curative surgery on survival and identify any favorable tumor or patient characteristics that might make surgical resection appropriate when treating stage IV esophageal cancer. Methods A retrospective review of 3,500 esophagectomies performed at our institution from 1985 to 2013 identified 52 (1.5{\%}) patients with stage IV esophageal cancer who underwent surgical resection with intent for cure. In 46 (88.5{\%}) patients, M1 disease was discovered at the time of surgery and 6 (11.5{\%}) patients had known M1 disease prior to surgery. Results Median age at the time of surgery was 60 years (range, 31 to 81 years). The majority of patients were men (82.7{\%}) with adenocarcinoma (88.5{\%}). Neoadjuvant therapy was used in 18 (34.6{\%}) patients; all patients operated on after 1999 received neoadjuvant therapy. An Ivor Lewis esophagectomy was performed in 39 (75{\%}) patients. Follow-up was complete in all patients for a median of 324 days (range, 4 days to 8.5 years). Overall, 1-year survival was 29{\%} and 5-year survival was 6{\%}. There was no significant difference in survival between patients with known preoperative versus intraoperative discovery of M1 disease. Factors associated with improved survival included neoadjuvant treatment, low T stage, and lack of alcohol use. Conclusions Few patients with stage IV esophageal cancer survive long term after surgical resection, though 5-year survival can occur. Our current recommendation is that esophagectomy should not be performed for stage IV disease.",
author = "Saddoughi, {Sahar A.} and Reinersman, {J. Matthew} and Zhukov, {Yuriy O.} and James Taswell and Kristin Mara and Harmsen, {S. William} and Blackmon, {Shanda H.} and Cassivi, {Stephen D.} and Francis Nichols and Shen, {K. Robert} and Wigle, {Dennis A} and Allen, {Mark S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.athoracsur.2016.06.070",
language = "English (US)",
volume = "103",
pages = "261--266",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Survival After Surgical Resection of Stage IV Esophageal Cancer

AU - Saddoughi, Sahar A.

AU - Reinersman, J. Matthew

AU - Zhukov, Yuriy O.

AU - Taswell, James

AU - Mara, Kristin

AU - Harmsen, S. William

AU - Blackmon, Shanda H.

AU - Cassivi, Stephen D.

AU - Nichols, Francis

AU - Shen, K. Robert

AU - Wigle, Dennis A

AU - Allen, Mark S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Five-year survival of stage IV esophageal cancer is rare. The treatment of advanced esophageal cancer is typically palliative and the role of surgery remains controversial. We sought to understand the impact of curative surgery on survival and identify any favorable tumor or patient characteristics that might make surgical resection appropriate when treating stage IV esophageal cancer. Methods A retrospective review of 3,500 esophagectomies performed at our institution from 1985 to 2013 identified 52 (1.5%) patients with stage IV esophageal cancer who underwent surgical resection with intent for cure. In 46 (88.5%) patients, M1 disease was discovered at the time of surgery and 6 (11.5%) patients had known M1 disease prior to surgery. Results Median age at the time of surgery was 60 years (range, 31 to 81 years). The majority of patients were men (82.7%) with adenocarcinoma (88.5%). Neoadjuvant therapy was used in 18 (34.6%) patients; all patients operated on after 1999 received neoadjuvant therapy. An Ivor Lewis esophagectomy was performed in 39 (75%) patients. Follow-up was complete in all patients for a median of 324 days (range, 4 days to 8.5 years). Overall, 1-year survival was 29% and 5-year survival was 6%. There was no significant difference in survival between patients with known preoperative versus intraoperative discovery of M1 disease. Factors associated with improved survival included neoadjuvant treatment, low T stage, and lack of alcohol use. Conclusions Few patients with stage IV esophageal cancer survive long term after surgical resection, though 5-year survival can occur. Our current recommendation is that esophagectomy should not be performed for stage IV disease.

AB - Background Five-year survival of stage IV esophageal cancer is rare. The treatment of advanced esophageal cancer is typically palliative and the role of surgery remains controversial. We sought to understand the impact of curative surgery on survival and identify any favorable tumor or patient characteristics that might make surgical resection appropriate when treating stage IV esophageal cancer. Methods A retrospective review of 3,500 esophagectomies performed at our institution from 1985 to 2013 identified 52 (1.5%) patients with stage IV esophageal cancer who underwent surgical resection with intent for cure. In 46 (88.5%) patients, M1 disease was discovered at the time of surgery and 6 (11.5%) patients had known M1 disease prior to surgery. Results Median age at the time of surgery was 60 years (range, 31 to 81 years). The majority of patients were men (82.7%) with adenocarcinoma (88.5%). Neoadjuvant therapy was used in 18 (34.6%) patients; all patients operated on after 1999 received neoadjuvant therapy. An Ivor Lewis esophagectomy was performed in 39 (75%) patients. Follow-up was complete in all patients for a median of 324 days (range, 4 days to 8.5 years). Overall, 1-year survival was 29% and 5-year survival was 6%. There was no significant difference in survival between patients with known preoperative versus intraoperative discovery of M1 disease. Factors associated with improved survival included neoadjuvant treatment, low T stage, and lack of alcohol use. Conclusions Few patients with stage IV esophageal cancer survive long term after surgical resection, though 5-year survival can occur. Our current recommendation is that esophagectomy should not be performed for stage IV disease.

UR - http://www.scopus.com/inward/record.url?scp=84995489109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995489109&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2016.06.070

DO - 10.1016/j.athoracsur.2016.06.070

M3 - Article

C2 - 27623270

AN - SCOPUS:84995489109

VL - 103

SP - 261

EP - 266

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -